Recro Pharma (NASDAQ:REPH) posted its earnings results on Wednesday. The specialty pharmaceutical company reported ($0.64) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.67) by $0.03, MarketWatch Earnings reports. Recro Pharma had a negative net margin of 75.19% and a negative return on equity of 144.84%. The firm had revenue of $18.28 million for the quarter, compared to analyst estimates of $16.77 million. Recro Pharma updated its FY 2018 guidance to EPS.
REPH traded up $0.16 during trading on Friday, reaching $7.35. 115,327 shares of the company’s stock were exchanged, compared to its average volume of 150,451. Recro Pharma has a one year low of $4.78 and a one year high of $13.05. The company has a debt-to-equity ratio of 2.22, a current ratio of 1.59 and a quick ratio of 1.42. The firm has a market capitalization of $147.30 million, a price-to-earnings ratio of -3.69 and a beta of -0.51.
A number of equities research analysts have weighed in on REPH shares. Oppenheimer set a $18.00 target price on shares of Recro Pharma and gave the stock a “buy” rating in a report on Wednesday, August 8th. ValuEngine lowered shares of Recro Pharma from a “buy” rating to a “hold” rating in a report on Monday, September 17th. Janney Montgomery Scott set a $13.00 target price on shares of Recro Pharma and gave the stock a “buy” rating in a report on Monday, October 1st. Zacks Investment Research raised shares of Recro Pharma from a “hold” rating to a “strong-buy” rating and set a $8.25 target price on the stock in a report on Wednesday. Finally, Piper Jaffray Companies set a $10.00 target price on shares of Recro Pharma and gave the stock a “buy” rating in a report on Thursday. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $12.88.
TRADEMARK VIOLATION WARNING: “Recro Pharma (REPH) Issues Earnings Results” was first posted by WKRB News and is the property of of WKRB News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.wkrb13.com/2018/11/09/recro-pharma-reph-issues-earnings-results.html.
About Recro Pharma
Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Recommended Story: Why is the conference call important?
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.